Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CAPR
CUSIPN/A
Phone310-358-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio9.94
Quick Ratio9.94
Price-To-Earnings
Trailing P/E Ratio-3.16
Forward P/E Ratio-2.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.67 million
Price / Sales15.15
Cash FlowN/A
Price / CashN/A
Book Value$0.44 per share
Price / Book3.16
Profitability
EPS (Most Recent Fiscal Year)($0.44)
Net Income$2.43 million
Net Margins110.98%
Return on Equity-485.43%
Return on Assets-85.83%
Miscellaneous
Employees40
Outstanding Shares29,110,000
Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."
How were Capricor Therapeutics' earnings last quarter?
Capricor Therapeutics Inc (NASDAQ:CAPR) announced its earnings results on Wednesday, March, 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. The biotechnology company earned $0.48 million during the quarter, compared to analyst estimates of $0.63 million. Capricor Therapeutics had a net margin of 110.98% and a negative return on equity of 485.43%. View Capricor Therapeutics' Earnings History.
When is Capricor Therapeutics' next earnings date?
What price target have analysts set for CAPR?
3 brokers have issued 1 year price targets for Capricor Therapeutics' stock. Their forecasts range from $2.15 to $9.00. On average, they anticipate Capricor Therapeutics' share price to reach $6.05 in the next twelve months. View Analyst Ratings for Capricor Therapeutics.
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include Sol Gel Technologies (SLGL), Nabriva Therapeutics (NBRV), Newron Pharmaceuticals (NWPHF), Conatus Pharmaceuticals (CNAT), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), XBiotech (XBIT), Eleven Biotherapeutics (EBIO), MEI Pharma (MEIP), Fortress Biotech (FBIO), Zynerba Pharmaceuticals (ZYNE), Protagonist Therapeutics (PTGX), Cerecor (CERC), Chembio Diagnostics (CEMI), Emisphere Technologies (EMIS) and Bellerophon Therapeutics (BLPH).
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
- Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
- Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
- Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
- Deborah Ascheim M.D., Chief Medical Officer
- Joshua A. Kazam, Director (Age 40)
Has Capricor Therapeutics been receiving favorable news coverage?
News stories about CAPR stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Capricor Therapeutics earned a daily sentiment score of 0.22 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 44.90 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Capricor Therapeutics?
Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
One share of CAPR stock can currently be purchased for approximately $1.39.
How big of a company is Capricor Therapeutics?
Capricor Therapeutics has a market capitalization of $41.63 million and generates $2.67 million in revenue each year. The biotechnology company earns $2.43 million in net income (profit) each year or ($0.44) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.
How can I contact Capricor Therapeutics?
Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]
MarketBeat Community Rating for Capricor Therapeutics (CAPR)
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
